

### IN THE CLAIMS

Please amend the claims as follows:

1-44. (Cancelled)

45. (Currently Amended) A topical lotion, comprising:

about 0.005 to 1.0 wt.% fluticasone, or a pharmaceutically acceptable salt or ester thereof;

about 4.0 to 6.0 wt.% of a C<sub>14</sub>-C<sub>20</sub> fatty alcohol or mixtures thereof;

about 1.0 to 5.0 wt.% of at least one first skin conditioning agent;

about 5.0 to 15.0 wt.% propylene glycol; and

the balance in water;

wherein the lotion is free of mineral oil and white soft paraffin, and

wherein the lotion causes more vasoconstriction when applied to living human skin than does application of a cream containing mineral oil or soft white paraffin, or both, the cream containing the same amount of the fluticasone or the pharmaceutically acceptable salt or ester thereof.

46. (Previously Presented) The lotion of Claim 45 further comprising about 0.25 to 3.0 wt.% of at least one surfactant.

47. (Previously Presented) The lotion of Claim 45 further comprising about 0.5 to 2.0 wt.% of at least one surfactant.

48. (Previously Presented) The lotion of Claim 45 further comprising dimethicone in an amount up to about 5.0 wt.%.

49. (Previously Presented) The lotion of Claim 48 further comprising about 0.5 to 3.0 wt.% of dimethicone.

50. (Previously Presented) The lotion of Claim 48 further comprising about 1.0 to 2.0 wt.% of dimethicone.
51. (Previously Presented) The lotion of Claim 49 wherein said C<sub>14</sub>-C<sub>20</sub> fatty alcohol or mixtures thereof is cetostearyl alcohol.
52. (Previously Presented) The lotion of Claim 51 wherein said first skin conditioning agent is isopropyl myristate.
53. (Previously Presented) The lotion of Claim 52 further comprising about 0.25 to 3.0 wt.% of at least one surfactant.
54. (Previously Presented) The lotion of Claim 52 further comprising about 0.5 to 2.0 wt.% of at least one surfactant.
55. (Previously Presented) The lotion of Claim 54 wherein said surfactant is Cetomacrogol.
56. (Currently Amended) The lotion of Claim 55 further comprising one or more buffers.
57. (Currently Amended) The lotion of Claim 56 further comprising one or more preservatives.
58. (Previously Presented) The lotion of Claim 57 wherein said fluticasone, or a pharmaceutically acceptable salt or ester thereof is fluticasone propionate.
59. (Previously Presented) The lotion of Claim 58 wherein said one or more buffer is selected from the group consisting of: sodium citrate and citric acid.
60. (Previously Presented) The lotion of Claim 59 wherein said one or more preservative is selected from the group consisting of: imidurea, methylparaben, and propylparaben.

61. (Previously Presented) A method of treating a skin condition, comprising topically administering to a patient in need thereof a lotion according to Claim 58.
62. (Previously Presented) The method of Claim 59 wherein said skin condition is selected from the group consisting of: corticosteroid-responsive dermatosis, atopic dermatitis, inflammation, eczema, erythema, papulation, scaling, erosion, oozing, crusting and pruritis.
63. (Currently Amended) A topical lotion, comprising:  
about 0.05 wt.% fluticasone, or a pharmaceutically acceptable salt or ester thereof;  
about 4.0 to 6.0 wt.% of cetostearyl alcohol;  
about 1.0 to 2.0 wt.% of isopropyl myristate;  
about 5.0 to 15.0 wt.% propylene glycol;  
about 0.5 to 3.0 wt.% of dimethicone;  
about 0.25 to 3.0 wt.% of at least one surfactant; and  
the balance in water;  
wherein the lotion is free of mineral oil and white soft paraffin, and  
wherein the lotion causes more vasoconstriction when applied to living human skin than  
does application of a cream containing mineral oil or soft white paraffin, or both, the cream  
containing the same amount of the fluticasone or the pharmaceutically acceptable salt or ester  
thereof.
64. (Cancelled)